125 related articles for article (PubMed ID: 35900648)
1. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Kantor O; Burstein HJ; King TA; Shak S; Russell CA; Giuliano AE; Hortobagyi GN; Winer EP; Korde LA; Sparano JA; Mittendorf EA
Ann Surg Oncol; 2022 Dec; 29(13):8016-8023. PubMed ID: 35900648
[TBL] [Abstract][Full Text] [Related]
2. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
4. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
[TBL] [Abstract][Full Text] [Related]
5. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
Kantor O; King TA; Shak S; Russell CA; Giuliano AE; Hortobagyi GN; Burstein HJ; Winer EP; Dey T; Sparano JA; Mittendorf EA
J Natl Cancer Inst; 2021 Nov; 113(12):1744-1750. PubMed ID: 34010423
[TBL] [Abstract][Full Text] [Related]
6. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
[TBL] [Abstract][Full Text] [Related]
7. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
[TBL] [Abstract][Full Text] [Related]
8. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.
Xiang HY; Liu YH; Zhang H; Zhang S; Xin L; Xu L; Ye JM; Li T; Duan XN; Liu Q
Chin Med J (Engl); 2019 Dec; 132(24):2914-2919. PubMed ID: 31809316
[TBL] [Abstract][Full Text] [Related]
10. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
11. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
12. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
14. OncotypeDX Testing Does Not Benefit Patients with Estrogen and Progesterone Receptor Positive Grade 1 Breast Cancers: A TAILORx Validated Study.
Sibia US; Mylander C; Martin T; Rosman M; Sanders TJ; Lee Y; Tafra L; Jackson RS
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):412-419. PubMed ID: 37363979
[TBL] [Abstract][Full Text] [Related]
15. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.
Xu L; Li JH; Ye JM; Duan XN; Cheng YJ; Xin L; Liu Q; Zhou B; Liu YH
Chin Med J (Engl); 2017 Aug; 130(16):1945-1952. PubMed ID: 28776547
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.
Zhou B; Xu L; Ye J; Xin L; Duan X; Liu Y
Anticancer Res; 2017 Aug; 37(8):4615-4621. PubMed ID: 28739761
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Ding S; Wu J; Lin C; Andriani L; Goh C; Chen W; Li Y; Shen K; Zhu L
Oncologist; 2019 Nov; 24(11):e1014-e1023. PubMed ID: 31019021
[TBL] [Abstract][Full Text] [Related]
19. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
20. 21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy.
Chevli N; Haque W; Tran KT; Farach AM; Schwartz MR; Hatch SS; Butler EB; Teh BS
Radiother Oncol; 2022 Sep; 174():37-43. PubMed ID: 35772577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
